Cite
HARVARD Citation
Dreno, B. et al. (2018). MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet oncology. 19 (7), pp. 916-929. [Online].